U.S. Markets open in 3 hrs 25 mins

BioMarin Stock Is a Buy, With or Without Hemophilia Treatment, J.P. Morgan Says

Josh Nathan-Kazis

J.P. Morgan analyst Cory Kasimov said Wednesday that BioMarin is undervalued. He said the firm is in strong shape, even if its gene-therapy results are disappointing.